LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial

LP‐003, a novel high‐affinity anti‐IgE antibody for inadequately controlled seasonal allergic rhinitis: A multicenter, randomized, double‐blind, placebo‐controlled phase 2 clinical trial

Abstract Background Anti‐IgE therapy can serve as an option for inadequately controlled seasonal allergic rhinitis (SAR) patients. LP‐003, a novel anti‐IgE antibody, is being tested as an add‐on treatment for SAR. This trial aimed to evaluate whether LP‐003 is effective and safe for SAR. Methods Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kai Guan, Shuang Liu, Yan Feng, Lisha Li, Xiaoming Zhu, Nai‐Chau‐Sun Bill, Haili Ma, Jie Yang, Cuicui Han, Heng Liu, Qingyu Wei, Haiyun Shi, Xueyan Wang
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Clinical and Translational Allergy
Subjects:
anti‐IgE antibody
nasal symptom
RCT
seasonal allergic rhinitis
uncontrolled
Online Access:https://doi.org/10.1002/clt2.70074
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/clt2.70074

Similar Items